Cell & Gene Therapies

Pricing and Market Access Considerations for Cell and Gene

2020-03-04T22:43:35+00:00February 27th, 2020|Categories: Blog|Tags: , , , |

Pricing and Market Access Considerations for Cell and Gene In the past two years, four cell and gene therapies have entered the U.S. market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million for a one-time treatment. Payers view these new therapies as having moderate to high clinical value but have significant concerns around long term durability of effect. For example, will [...]

Comments Off on Pricing and Market Access Considerations for Cell and Gene

An Overview of Cell and Gene Therapies

2020-03-04T13:53:10+00:00February 24th, 2020|Categories: Blog|Tags: , , , |

An Overview of Cell and Gene Therapies Since 2017, four new cell and gene therapies have become available in the U.S. with prices ranging from $373,000 to $2.1 million for a one-time administration. Gene Therapy Launch Timeline Gene Therapy Product Overview [fusion_table fusion_table_type="1" fusion_table_rows="5" fusion_table_columns="4" hide_on_mobile="small-visibility,medium-visibility,large-visibility" class="" id="" animation_type="" animation_direction="left" animation_speed="0.3" animation_offset=""] Product Indication Therapy Type Price Kymriah Childhood B-cell [...]

Comments Off on An Overview of Cell and Gene Therapies

Innovative Access Agreements

2020-05-13T15:05:43+00:00January 1st, 2019|Categories: Blog|Tags: , , |

A potential payer solution for Cell & Gene Therapies A US and European perspective Payer concerns over increasing cost of therapies and uncertainty of clinical data have led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). For the purpose of this review we will refer to them collectively as IAA. The [...]

Comments Off on Innovative Access Agreements

MKO Minute – Rise of Gene Therapy

2020-02-26T15:23:43+00:00May 30th, 2017|Categories: Blog|Tags: , , |

This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents. How will payers pay for these new gene therapies? Did Novartis set the price reference for Juno’s and Gilead/Kite’s CAR-T entrants?

Comments Off on MKO Minute – Rise of Gene Therapy
Go to Top